The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genomic Research Centers
National Institutes of Health
Classification and identifiers
- Solicitation number
- RFA-DK-27-116
- Assistance listing (CFDA)
- 93.847
Amount
Amount not published by the funder
Who can apply
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
The National Institute of Diabetes and Digestive Diseases and Nutrition (NIDDK) seeks to advance its mission by continuing the NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC). The IBDGC has led collaborative efforts resulting in the identification of >300 genetic risk loci for different IBD subtypes across patient populations and characterization of underlying biological mechanisms. Despite advances in biological understanding and the development of a range of biologic therapies, IBD remains a chronic, severe and heterogenous disease with no cure requiring multiple interventions over the life course. Diagnostic biomarkers and accurate predictors of critical outcomes including disease remission, recurrence, and response to specific therapies are lacking. The IBDGC will leverage...
Related opportunities
- The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Data Coordinating CenterNational Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium Clinical Centers (DGIC)National Institutes of Health
- Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01 Clinical Trial Not Allowed)National Institutes of Health
- IDeA Networks of Biomedical Research Excellence (INBRE)National Institutes of Health
- Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01 Clinical Trial Not Allowed)National Institutes of HealthCloses in 2 days
- Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional)National Institutes of HealthCloses in 80 days